[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Eva Bonfill\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":65},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,41],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100479779","phase-2-safety-tolerance-and-antiretroviral-activity-of-dasatinib-a-pilot-clinical-trial-in-patients-with-recent-hiv-1-infection-100479779",false,"NCT05527418","Safety, Tolerance and Antiretroviral Activity of Dasatinib: a Pilot Clinical Trial in Patients With Recent HIV-1 Infection","DASAHIVCURE","Inclusion Criteria:\n\n* 18 to 65 years.\n* Documented asymptomatic HIV-1 infection of 3-12 months duration (all patients must have a positive Western blot, including the p31 band whose appearance indicates infection of more than 90 days duration).\n* Not having received ART\n* CD4 T-lymphocyte count\\> 350 \u002F μl\n* Patient giving written informed consent\n\nExclusion Criteria:\n\n* Active HBV (HBsAg+ or DNA+) and\u002For HCV (RNA+) infection in screening.\n* ALT\\> 2 UNL, glomerular filtration rate \\\u003C70 mL \u002F 1.73 m2, leukocytes \\\u003C4000 \u002F mm3, total lymphocyte count \\\u003C1000 \u002F mm3, platelets \\\u003C100,000 \u002F mm3 or Hg \\\u003C12g \u002F dL.\n* Pregnancy or active breastfeeding\n* Ongoing or previous pleural effusion\n* Chronic obstructive pulmonary disease, bronchial asthma or recent chest trauma.\n* History of gastrointestinal or other bleeding.\n* Any concomitant treatment with potentially dangerous drug interaction with dasatinib.\n* Any clinical condition, at the opinion of the investigator, contraindicating participation (for example,\n* Active neoplastic disease, active concomitant infection, etc.)","ALL","18 Years","65 Years",{"count":20,"type":21},24,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","Study to evaluate the safety, tolerability and antiretroviral activity of a new therapeutic strategy, based on the administration of dasatinib, an ITK, in patients with recent (3-12 months) asymptomatic HIV-1 infection.",[27],"Recent HIV-1 Infection","RECRUITING","2025-04-30",{"date":31,"type":32},"2025-05-01","ACTUAL",{"date":34,"type":32},"2024-01-26",{"date":36,"type":21},"2026-06",{"name":38,"class":39},"Eva Bonfill","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":22,"phases":51,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":40},"100499469","phase-4-trial-comparing-conventional-antibiotic-strategies-versus-regimens-guided-by-epidemiological-surveillance-in-infected-patients-with-cirrhosis-survicstudy-100499469","NCT05783661","Trial Comparing Conventional Antibiotic Strategies Versus Regimens Guided by Epidemiological Surveillance in Infected Patients With Cirrhosis (SURVIC_STUDY)","Randomized Controlled Trial Comparing Conventional Antibiotic Strategies Versus Regimens Guided by Epidemiological Surveillance in Infected Patients With Cirrhosis","SURVIC","Inclusion Criteria:\n\n1. Cirrhotic patients with acute decompensation aged ≥18 years.\n2. Proven or suspected bacterial infection requiring antibiotic therapy (diagnosis will be established according to local guidelines, Appendix 1).\n3. Signed informed consent or consent given by their legal representatives or close relatives.\n\nExclusion Criteria:\n\n1. Bacterial infection lasting for \\> 48 hours.\n2. Infection in a critically ill cirrhotic patient (ICU admission). In this population, epidemiological surveillance is standard clinical practice.\n3. Evidence of current locally advanced or metastatic malignancy (patients with hepatocellular carcinoma within the Milan criteria and non-melanocytic skin cancer can be included).\n4. Pregnant and\u002For breast-feeding woman.\n5. Patients who cannot provide prior informed consent and when there is documented evidence that the patient has no legal surrogate decision-maker and it appears unlikely that the patient will regain consciousness or sufficient ability to provide delayed informed consent.",{"count":50,"type":21},198,[52],"PHASE4","Study to comparing conventrional antibiotic strategies versus regimens guided by epidemiological surveillance in infected patients with cirrhosis.",[55,56],"Decompensated Cirrhosis","Bacterial Infections","2024-09-26",{"date":59,"type":32},"2024-09-27",{"date":61,"type":32},"2023-12-11",{"date":63,"type":21},"2026-08",{"name":38,"class":39},""]